Loading...
•
Dec 31, 2025
Axogen Q4 2025 Earnings Report
Axogen Q4 2025 Earnings Report
Key Takeaways
Axogen delivered strong Q4 2025 revenue growth of 21.3% year-over-year, driven by broad-based performance across all market segments. The quarter was highlighted by the landmark FDA BLA approval of Avance®, though net income was impacted by one-time costs related to this milestone.
Q4 revenue reached $59.9 million, a 21.3% increase compared to the prior year.
The FDA approved the Biologics License Application (BLA) for Avance® on December 3, 2025.
Gross margin of 74.1% included 3% in one-time costs primarily related to non-cash stock compensation from the BLA approval.
Strengthened balance sheet post-quarter with a $133.3 million public offering used to fully repay the Oberland loan facility.
Forward Guidance
Axogen expects continued growth in 2026 with revenue increasing at least 18% and a return to positive free cash flow.
Positive Outlook
- Expected 2026 revenue of at least $265.7 million.
- Anticipated to be free cash flow positive for the full year 2026.
- New Level 3 Nerve Procedure Code effective Jan 2026 increasing facility reimbursement.
- Full repayment of Oberland loan facility in January 2026.
- Commercial payer coverage now exceeds 65%.
Challenges Ahead
- Gross margin guidance range of 74% to 76% remains consistent with recent levels.
- Potential disruptions from global supply chain issues.
- Ongoing hospital staffing challenges.
- Inflationary pressures.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...